CCM Investment Advisers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-16,009
| Closed | -$821K | – | 77 |
|
|
2023
Q4 | $821K | Sell |
16,009
-179,014
| -92% | -$9.4M | 0.1% | 63 |
|
|
2023
Q3 | $11.3M | Buy |
195,023
+4,698
| +2% | +$288K | 1.56% | 34 |
|
|
2023
Q2 | $12.2M | Buy |
190,325
+8,063
| +4% | +$541K | 1.63% | 29 |
|
|
2023
Q1 | $12.6M | Buy |
182,262
+28,911
| +19% | +$2.04M | 1.79% | 24 |
|
|
2022
Q4 | $11M | Sell |
153,351
-10,278
| -6% | -$775K | 1.75% | 31 |
|
|
2022
Q3 | $11.6M | Sell |
163,629
-5,413
| -3% | -$393K | 1.98% | 23 |
|
|
2022
Q2 | $13M | Sell |
169,042
-1,925
| -1% | -$147K | 2.09% | 16 |
|
|
2022
Q1 | $12.5M | Buy |
170,967
+14,354
| +9% | +$964K | 1.7% | 30 |
|
|
2021
Q4 | $9.76M | Sell |
156,613
-44,608
| -22% | -$2.62M | 1.18% | 51 |
|
|
2021
Q3 | $11.9M | Buy |
201,221
+6,421
| +3% | +$423K | 1.55% | 38 |
|
|
2021
Q2 | $13M | Buy |
194,800
+29,360
| +18% | +$1.91M | 1.67% | 32 |
|
|
2021
Q1 | $10.4M | Buy |
165,440
+8,339
| +5% | +$519K | 1.41% | 45 |
|
|
2020
Q4 | $9.74M | Buy |
157,101
+842
| +0.5% | +$51.8K | 1.41% | 45 |
|
|
2020
Q3 | $9.42M | Buy |
156,259
+407
| +0.3% | +$24.5K | 1.53% | 39 |
|
|
2020
Q2 | $9.16M | Buy |
155,852
+16,545
| +12% | +$990K | 1.56% | 37 |
|
|
2020
Q1 | $7.76M | Buy |
139,307
+135,807
| +3,880% | +$8.3M | 1.55% | 38 |
|
|
2019
Q4 | $224K | Buy |
+3,500
| New | +$200K | 0.03% | 68 |
|
|
2018
Q4 | – | Sell |
-3,695
| Closed | -$229K | – | 85 |
|
|
2018
Q3 | $229K | Sell |
3,695
-560
| -13% | -$33.2K | 0.04% | 84 |
|
|
2018
Q2 | $235K | Sell |
4,255
-515
| -11% | -$27.8K | 0.04% | 81 |
|
|
2018
Q1 | $301K | Sell |
4,770
-225
| -5% | -$14.5K | 0.06% | 70 |
|
|
2017
Q4 | $306K | Sell |
4,995
-615
| -11% | -$38.5K | 0.06% | 75 |
|
|
2017
Q3 | $357K | Sell |
5,610
-600
| -10% | -$35K | 0.07% | 74 |
|
|
2017
Q2 | $346K | Sell |
6,210
-9,000
| -59% | -$490K | 0.07% | 74 |
|
|
2017
Q1 | $827K | Sell |
15,210
-4,340
| -22% | -$238K | 0.16% | 68 |
|
|
2016
Q4 | $1.14M | Sell |
19,550
-89,510
| -82% | -$4.89M | 0.24% | 64 |
|
|
2016
Q3 | $5.88M | Sell |
109,060
-160,571
| -60% | -$10.3M | 1.24% | 47 |
|
|
2016
Q2 | $19.8M | Sell |
269,631
-363
| -0.1% | -$25.6K | 1.85% | 16 |
|
|
2016
Q1 | $17.2M | Buy |
269,994
+263,308
| +3,938% | +$16.6M | 1.62% | 36 |
|
|
2015
Q4 | $459K | Sell |
6,686
-142
| -2% | -$9.38K | 0.04% | 79 |
|
|
2015
Q3 | $404K | Sell |
6,828
-1,372
| -17% | -$87K | 0.04% | 85 |
|
|
2015
Q2 | $545K | Sell |
8,200
-375
| -4% | -$24.7K | 0.05% | 90 |
|
|
2015
Q1 | $553K | Sell |
8,575
-1,180
| -12% | -$73.9K | 0.05% | 92 |
|
|
2014
Q4 | $575K | Buy |
9,755
+30
| +0.3% | +$1.69K | 0.05% | 82 |
|
|
2014
Q3 | $497K | Sell |
9,725
-1,125
| -10% | -$56.2K | 0.04% | 84 |
|
|
2014
Q2 | $526K | Sell |
10,850
-495
| -4% | -$24.4K | 0.05% | 82 |
|
|
2014
Q1 | $589K | Sell |
11,345
-2,865
| -20% | -$152K | 0.06% | 89 |
|
|
2013
Q4 | $755K | Sell |
14,210
-2,815
| -17% | -$143K | 0.07% | 88 |
|
|
2013
Q3 | $787K | Sell |
17,025
-212
| -1% | -$9.31K | 0.08% | 95 |
|
|
2013
Q2 | $770K | Buy |
+17,237
| New | +$748K | 0.08% | 96 |
|
Other funds holding BMY
CCM Investment Advisers's BMY Position: Q1 2024 in Review
CCM Investment Advisers sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 16,009 shares — an estimated $821K sold.
CCM Investment Advisers first reported a position in BMY in Q2 2013 and held it in 39 quarters. The position peaked at $19.8M in Q2 2016. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.
- CCM Investment Advisers reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
- CCM Investment Advisers sold 16,009 Bristol-Myers Squibb shares in Q1 2024, an estimated $821K.
- CCM Investment Advisers first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 39 quarters.
- CCM Investment Advisers's Bristol-Myers Squibb position peaked at $19.8M in Q2 2016.
- 2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.
Based on CCM Investment Advisers's 13F filing for Q1 2024, filed 17 May 2024.